Nuclera has appointed Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera’s Co-founder and former CEO, transitions to the role of Chief Scientific and Business Officer, continuing to provide scientific leadership while supporting market development and strategic partnerships. The leadership transition reportedly marks the… Read More
Nuclera has announced the launched of a nanodisc panel focused on supporting G-Protein Coupled Receptors (GPCR) research and streamlining membrane protein production. Building on the eProtein Discovery membrane protein workflow capabilities, the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of challenging therapeutic targets, GPCRs, producing active… Read More
Biotechnology company Nuclera has partnered with leadXpro on structure-based drug design for complex membrane proteins. The collaboration will bring together Nuclera’s eProtein Discovery system with leadXpro’s AI/ML-driven construct design and membrane protein expertise to advance structural studies and therapeutic development. Membrane proteins remain some of the most valuable yet difficult to obtain drug targets. The proteins are notoriously challenging… Read More
Biotechnology company Nuclera has extended its Series C financing to $87 million to advance antibody engineering. The financing round, led by Elevage Medical Technologies and Jonathan Milner, was extended by $12 million following earlier investment worth $75 million. The funding is set to support Nuclera’s development of eProtein discovery for full-format antibody expression, purification and… Read More
Biotechnology company Nuclera has signed a partnership with life science provider Solve Scientific Australia, expanding access to eProtein Discovery for customers in Australia and New Zealand. Nuclera says its eProtein Discovery System provides rapid and easy access to functional proteins. According to the company, by applying digital microfluidics alongside in situ… Read More
Biotechnology company Nuclera and life sciences organisation Cytiva have announced a collaboration focused on accelerating the production, purification and characterisation of proteins required for drug research and development. The companies aim to enable this goal through the combination of Nuclera’s eProtein Discovery System with Cytiva’s Biacore surface plasmon resonance (SPR) technology. Read More
Nuclera has announced the addition of a new membrane protein workflow to its benchtop eProtein Discovery system. The company says this addition will allow the expression, purification and stabilisation of challenging membrane proteins, which are often key targets in therapeutic development. Using cell-free protein synthesis,… Read More
Biotech Nuclera has been awarded two Innovate UK grants totalling £1.14 ($1.4) million to further develop its eProtein Discovery platform. The funding is made up of a flexible, agile, scalable, and sustainable technologies (FASST) grant awarded in collaboration with DeepMirror, and an Engineering Biology grant. Read More
